{"gene":"GINS1","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2017,"finding":"Biallelic loss-of-function mutations in GINS1 impair GINS complex assembly, cause basal replication stress, impaired checkpoint signaling, defective cell cycle control, and genomic instability in patient fibroblasts; residual GINS1 activity (3–16%) correlated with severity of growth retardation and cellular phenotype. Wild-type GINS1 rescued these defects, establishing GINS1 as essential for eukaryotic DNA replication complex function.","method":"Patient fibroblast studies (genetic rescue with WT GINS1, cell cycle analysis, checkpoint signaling assays, genomic instability assays); compound heterozygous mutation analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal cellular assays (replication stress, checkpoint, cell cycle, genomic instability) with genetic rescue, replicated across 5 patients from 4 kindreds","pmids":["28414293"],"is_preprint":false},{"year":2022,"finding":"GINS1 physically interacts with TOP2A (Topoisomerase IIα) and promotes glioma cell proliferation and migration through USP15-mediated deubiquitination of TOP2A protein, thereby stabilizing TOP2A.","method":"Co-immunoprecipitation (physical interaction), functional assays (proliferation, migration in vitro and in vivo), mechanistic deubiquitination assays","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional rescue, single lab, two orthogonal methods","pmids":["36065190"],"is_preprint":false},{"year":2021,"finding":"MALAT1 lncRNA stabilizes FOXP3 protein by binding to its zinc finger (ZF) and leucine zipper (LZ) domains, masking the STUB1 E3 ligase interaction interface and inhibiting K48-linked ubiquitination/degradation of FOXP3; stabilized FOXP3 then acts as a transcription factor driving GINS1 expression, thereby promoting NSCLC proliferation.","method":"Co-IP, domain mapping, luciferase reporter assay, in vitro/in vivo knockdown and rescue experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with domain mapping plus luciferase reporter, single lab with multiple orthogonal methods","pmids":["33972684"],"is_preprint":false},{"year":2023,"finding":"NFIX transcription factor directly binds the GINS1 gene promoter (region −1779 to −1793 bp) and transcriptionally activates GINS1 expression; GINS1 is required for NFIX-driven GBM cell cycle progression and proliferation, and GINS1 replenishment rescues the anti-proliferative effect of NFIX knockdown.","method":"ChIP assay (promoter binding), luciferase reporter assay, genetic rescue experiments (GINS1 re-expression in NFIX-null cells)","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus luciferase reporter plus rescue, single lab, two orthogonal methods","pmids":["36469009"],"is_preprint":false},{"year":2023,"finding":"PAX5 transcription factor directly binds two sites in the GINS1 promoter and functions as a positive transcriptional activator of GINS1, as demonstrated by EMSA, ChIP, and luciferase assays; coordinated PAX5/GINS1 expression was validated in B cells and DLBCL cell lines.","method":"EMSA, ChIP assay, luciferase reporter assay","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — three orthogonal methods (EMSA, ChIP, luciferase), single lab","pmids":["37221950"],"is_preprint":false},{"year":2023,"finding":"FOXP1 transcription factor directly binds the GINS1 promoter and transcriptionally activates GINS1 expression; the FOXP1-GINS1 regulatory axis promotes DLBCL cell proliferation and confers doxorubicin resistance.","method":"EMSA, ChIP assay, luciferase reporter assay, in vivo xenograft model, CCK8/colony formation assays","journal":"Journal of Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — three orthogonal methods (EMSA, ChIP, luciferase) with in vivo validation, single lab","pmids":["37576391"],"is_preprint":false},{"year":2024,"finding":"E2F1 transcription factor directly binds the GINS1 promoter and activates GINS1 transcription; E2F1-driven GINS1 expression promotes HCC cell proliferation and stemness (as measured by colony formation, CCK-8, sphere formation); rescue experiments confirmed that overexpressed E2F1 offsets the suppressive effect of GINS1 silencing.","method":"ChIP assay, dual-luciferase reporter assay, genetic rescue (E2F1 OE in GINS1 KD cells), sphere/colony/CCK-8 assays","journal":"Journal of environmental pathology, toxicology and oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus luciferase plus rescue, single lab, multiple orthogonal methods","pmids":["37824372"],"is_preprint":false},{"year":2024,"finding":"OTUB2 deubiquitinase stabilizes SP1 protein by inhibiting its K48-linked ubiquitination; SP1 then binds the GINS1 promoter (region 1822–1830 bp) and transcriptionally activates GINS1, thereby driving stemness, chemoresistance, and EMT in colon cancer.","method":"Co-IP, ubiquitination assay, ChIP-qPCR, dual luciferase reporter assay, sphere formation, flow cytometry, cell viability assays","journal":"Cell communication and signaling : CCS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, ubiquitination, ChIP-qPCR, luciferase), single lab","pmids":["39210373"],"is_preprint":false},{"year":2021,"finding":"GINS1 knockdown causes G1/S cell cycle arrest and decreases tumor cell proliferation in HCC in vitro and in vivo; GINS1 promotes cancer stem cell activity (spheroid formation) and enhances HCC progression through activation of the HRAS signaling pathway; restoring HRAS partially rescued sorafenib resistance lost upon GINS1 knockdown.","method":"shRNA knockdown, cell cycle/proliferation assays, spheroid formation, xenograft mouse model, Western blot, RT-PCR, pathway rescue with HRAS overexpression","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined cellular phenotype plus pathway rescue, single lab, multiple methods","pmids":["34414190"],"is_preprint":false},{"year":2024,"finding":"GINS1 directly interacts with HRAS (confirmed by co-immunoprecipitation and GST pulldown) and activates HRAS signaling, thereby inducing liver cancer stem cell phenotype and promoting tumorigenesis; epicatechin (EC) attenuates this axis by enhancing DNA methylation on the GINS1 promoter, reducing GINS1 expression.","method":"Co-immunoprecipitation, GST pulldown assay, methylation-specific PCR, sphere formation, CCK-8, transwell, xenograft tumor model","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — direct protein interaction confirmed by two methods (Co-IP and GST pulldown) plus functional rescue, single lab","pmids":["40713555"],"is_preprint":false},{"year":2024,"finding":"GINS1 silencing inhibits the AKT/mTOR/c-Myc signaling pathway and causes G0/G1 cell cycle arrest in bladder cancer; conversely, increased GINS1 expression activates the AKT/mTOR pathway and accelerates bladder cancer progression in vitro and in vivo.","method":"siRNA knockdown, cell cycle/proliferation assays, colony formation, transwell migration, flow cytometry, Western blot, xenograft model","journal":"Experimental cell research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway assessment by Western blot only, no rescue or mutagenesis","pmids":["38880324"],"is_preprint":false},{"year":2024,"finding":"GINS1 promotes epithelial-mesenchymal transition (EMT) and HCC tumor metastasis through ZEB1 and the β-catenin signaling pathway; silencing GINS1 inhibits proliferation, migration, invasion and metastasis both in vitro and in vivo.","method":"shRNA knockdown, OE, EMT markers by Western blot, in vitro invasion/migration assays, in vivo xenograft/metastasis model","journal":"Journal of cellular physiology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway placement by Western blot without direct mechanistic validation of GINS1-β-catenin interaction","pmids":["38468464"],"is_preprint":false},{"year":2025,"finding":"GINS1 promotes LUAD progression by activating the Wnt/β-catenin signaling pathway; transcriptome sequencing linked GINS1 to G1/S cell cycle transition (cyclin D) and β-catenin signaling, which was validated by Western blot and rescue experiments.","method":"Transcriptome sequencing, Western blot, rescue experiments (β-catenin pathway modulation), in vitro proliferation/migration assays, in vivo xenograft","journal":"World journal of surgical oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway assessed by Western blot and rescue, no direct binding assay for GINS1-β-catenin","pmids":["40197379"],"is_preprint":false},{"year":2024,"finding":"GINS1 enhances glycolysis, proliferation, and metastasis in LUAD cells by upregulating Notch1 and Notch3 receptor expression, which activates downstream PI3K/AKT/mTORC1 signaling; Notch agonist Jagged1 reversed inhibition caused by GINS1 knockdown, and Notch inhibitor LY3039478 blocked enhancement caused by GINS1 overexpression.","method":"shRNA knockdown, OE, Western blot, glycolysis assays (glucose consumption, lactate production), colony formation, scratch, transwell, Notch agonist/inhibitor rescue experiments","journal":"Zhongguo fei ai za zhi = Chinese journal of lung cancer","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway evidence by Western blot plus pharmacological rescue, no direct mechanistic link established between GINS1 and Notch receptors","pmids":["39631830"],"is_preprint":false},{"year":2025,"finding":"GINS1 promotes EMT and tumor aggressiveness in cervical cancer by suppressing FYN kinase; GINS1 knockdown de-represses FYN and reduces EMT markers, establishing a GINS1/FYN/EMT regulatory axis.","method":"Transcriptome sequencing, in vitro functional assays (proliferation, migration, invasion, colony formation), xenograft model, Western blot and molecular analyses","journal":"Life sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway placement by transcriptomics and Western blot, no direct binding or enzymatic assay linking GINS1 to FYN","pmids":["41242545"],"is_preprint":false},{"year":2026,"finding":"GINS1 is a downstream target of POLE2 in renal cell carcinoma; GINS1 overexpression reverses the inhibitory effects of POLE2 knockdown on RCC proliferation, metastasis, and EMT, and restores autophagy suppression. POLE2/GINS1 inhibits AKT/mTOR-mediated autophagy, thereby promoting EMT and lung metastasis.","method":"Bioinformatics, in vitro/in vivo models, GINS1 OE rescue of POLE2 KD, Western blot, molecular biology assays","journal":"Apoptosis : an international journal on programmed cell death","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway evidence primarily by rescue and Western blot, no direct binding assay for POLE2-GINS1 interaction","pmids":["41893924"],"is_preprint":false}],"current_model":"GINS1 (PSF1/KIAA0186) is an essential subunit of the eukaryotic GINS complex required for DNA replication initiation and elongation; inherited partial loss-of-function mutations impair GINS complex assembly, cause replication stress, checkpoint defects, genomic instability, growth retardation, neutropenia, and NK cell deficiency. Beyond its core replication role, GINS1 expression is transcriptionally activated by multiple transcription factors (NFIX, PAX5, FOXP1, E2F1, SP1 downstream of OTUB2), and at the protein level GINS1 physically interacts with HRAS and TOP2A; the latter interaction is stabilized via USP15-mediated deubiquitination of TOP2A to drive glioma proliferation and migration, while GINS1-HRAS interaction promotes liver cancer stem cell properties, and GINS1 additionally modulates downstream oncogenic signaling (AKT/mTOR, Wnt/β-catenin, Notch/PI3K, FYN/EMT axes) across multiple cancer contexts."},"narrative":{"mechanistic_narrative":"GINS1 (PSF1) is an essential subunit of the eukaryotic GINS complex required for DNA replication, and biallelic loss-of-function mutations impair GINS complex assembly, producing basal replication stress, defective checkpoint signaling, impaired cell cycle control, and genomic instability, with residual GINS1 activity correlating with clinical severity in affected patients [PMID:28414293]. Beyond this core replication role, GINS1 expression is a convergence point for multiple oncogenic transcription factors that directly bind its promoter and activate transcription, including NFIX [PMID:36469009], PAX5 [PMID:37221950], FOXP1 [PMID:37576391], E2F1 [PMID:37824372], and SP1 acting downstream of OTUB2 [PMID:39210373]; FOXP3 stabilized by MALAT1 likewise drives GINS1 expression [PMID:33972684]. At the protein level GINS1 physically interacts with TOP2A, and through USP15-mediated deubiquitination and stabilization of TOP2A it promotes glioma proliferation and migration [PMID:36065190], and it directly binds HRAS to activate HRAS signaling and induce liver cancer stem cell phenotypes [PMID:34414190, PMID:40713555]. Across these contexts GINS1 supports the G1/S cell cycle transition and tumor cell proliferation [PMID:37824372, PMID:34414190].","teleology":[{"year":2017,"claim":"Whether GINS1 is genuinely essential for human DNA replication and how its dosage maps to disease was unknown; patient-derived mutations established GINS1 as required for GINS complex assembly and replication integrity.","evidence":"Patient fibroblast studies with WT GINS1 genetic rescue, checkpoint, cell cycle and genomic instability assays across 5 patients from 4 kindreds","pmids":["28414293"],"confidence":"High","gaps":["Does not resolve the structural basis of how specific mutations impair GINS subunit assembly","Does not address GINS1 function outside the replication context"]},{"year":2021,"claim":"It was unclear how GINS1 contributes to tumor aggressiveness beyond replication; loss-of-function studies linked GINS1 to HRAS pathway activation and cancer stem cell properties in HCC.","evidence":"shRNA knockdown with G1/S arrest, spheroid formation, xenografts and HRAS overexpression rescue","pmids":["34414190"],"confidence":"Medium","gaps":["Did not yet demonstrate a direct GINS1-HRAS physical interaction","Mechanism of HRAS pathway engagement by a replication factor unclear"]},{"year":2021,"claim":"How GINS1 transcription is upregulated in cancer was unaddressed; MALAT1-stabilized FOXP3 was shown to drive GINS1 expression in NSCLC.","evidence":"Co-IP, domain mapping, luciferase reporter, knockdown/rescue in vitro and in vivo","pmids":["33972684"],"confidence":"Medium","gaps":["Direct FOXP3 binding to the GINS1 promoter not mapped at nucleotide resolution","Single lab"]},{"year":2022,"claim":"Whether GINS1 has protein partners that act outside replication was open; GINS1 was shown to physically interact with TOP2A and stabilize it via USP15-mediated deubiquitination to drive glioma growth.","evidence":"Reciprocal Co-IP, deubiquitination assays, proliferation/migration assays in vitro and in vivo","pmids":["36065190"],"confidence":"Medium","gaps":["How GINS1 promotes USP15 recruitment to TOP2A not defined","Single lab without independent replication"]},{"year":2023,"claim":"The transcriptional control of GINS1 was clarified by identifying multiple direct promoter-binding activators across cancer types: NFIX, PAX5 and FOXP1.","evidence":"ChIP/EMSA promoter binding, luciferase reporter and rescue assays in GBM, B cells/DLBCL","pmids":["36469009","37221950","37576391"],"confidence":"Medium","gaps":["Whether these factors act combinatorially on the same promoter is unknown","Each shown in a distinct single-lab context"]},{"year":2024,"claim":"Additional transcriptional inputs were established, placing GINS1 downstream of E2F1 and of OTUB2-stabilized SP1.","evidence":"ChIP, dual-luciferase reporter, ubiquitination assays and rescue in HCC and colon cancer","pmids":["37824372","39210373"],"confidence":"Medium","gaps":["Hierarchy among the many GINS1 activators not resolved","Single lab per context"]},{"year":2024,"claim":"The earlier functional link to HRAS was upgraded to a direct physical interaction, defining a GINS1-HRAS axis driving liver cancer stem cell phenotypes.","evidence":"Co-IP and GST pulldown, methylation-specific PCR, sphere formation and xenografts","pmids":["40713555"],"confidence":"Medium","gaps":["Interaction interface and stoichiometry not mapped","Single lab"]},{"year":2024,"claim":"GINS1 was placed upstream of several oncogenic signaling cascades across tumor types, though largely by pathway-level readouts.","evidence":"Knockdown/overexpression with Western blot and pharmacological rescue assigning GINS1 to AKT/mTOR, β-catenin, Notch/PI3K and FYN/EMT axes","pmids":["38880324","38468464","39631830","41242545"],"confidence":"Low","gaps":["No direct binding or enzymatic assay linking GINS1 to these pathway nodes","Pathway placement rests on Western blot and rescue, prone to indirect effects"]},{"year":2026,"claim":"GINS1 was positioned as a downstream effector of POLE2 controlling AKT/mTOR-mediated autophagy in renal cell carcinoma.","evidence":"Bioinformatics with GINS1 overexpression rescue of POLE2 knockdown, in vitro/in vivo models, Western blot","pmids":["41893924"],"confidence":"Low","gaps":["No direct POLE2-GINS1 binding assay","Single lab, indirect pathway evidence"]},{"year":null,"claim":"How GINS1's essential replication function mechanistically intersects with its many reported oncogenic interactions and transcriptional inputs remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of GINS1 within the human GINS complex from the corpus","Whether non-replication interactions (HRAS, TOP2A) depend on or are separable from GINS complex assembly is unknown","Causal hierarchy among the numerous transcription factors driving GINS1 not established"]}],"mechanism_profile":{"molecular_activity":[],"localization":[],"pathway":[{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[0]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0]}],"complexes":["GINS complex"],"partners":["TOP2A","HRAS"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q14691","full_name":"DNA replication complex GINS protein PSF1","aliases":["GINS complex subunit 1"],"length_aa":196,"mass_kda":23.0,"function":"Required for correct functioning of the GINS complex, a complex that plays an essential role in the initiation of DNA replication, and progression of DNA replication forks (PubMed:17417653, PubMed:28414293). GINS complex is a core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232)","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/Q14691/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/GINS1","classification":"Common Essential","n_dependent_lines":1208,"n_total_lines":1208,"dependency_fraction":1.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GINS1","total_profiled":1310},"omim":[{"mim_id":"617827","title":"IMMUNODEFICIENCY 55; IMD55","url":"https://www.omim.org/entry/617827"},{"mim_id":"611291","title":"IMMUNODEFICIENCY 124, SEVERE COMBINED; IMD124","url":"https://www.omim.org/entry/611291"},{"mim_id":"611290","title":"NONHOMOLOGOUS END-JOINING FACTOR 1; NHEJ1","url":"https://www.omim.org/entry/611290"},{"mim_id":"610611","title":"GINS COMPLEX SUBUNIT 4; GINS4","url":"https://www.omim.org/entry/610611"},{"mim_id":"610610","title":"GINS COMPLEX SUBUNIT 3; GINS3","url":"https://www.omim.org/entry/610610"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":6.8},{"tissue":"testis","ntpm":8.3}],"url":"https://www.proteinatlas.org/search/GINS1"},"hgnc":{"alias_symbol":["KIAA0186","PSF1"],"prev_symbol":[]},"alphafold":{"accession":"Q14691","domains":[{"cath_id":"1.20.58.1030","chopping":"3-126","consensus_level":"high","plddt":94.9023,"start":3,"end":126},{"cath_id":"3.40.5","chopping":"146-192","consensus_level":"high","plddt":91.3257,"start":146,"end":192}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14691","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14691-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14691-F1-predicted_aligned_error_v6.png","plddt_mean":93.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GINS1","jax_strain_url":"https://www.jax.org/strain/search?query=GINS1"},"sequence":{"accession":"Q14691","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14691.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14691/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14691"}},"corpus_meta":[{"pmid":"28414293","id":"PMC_28414293","title":"Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28414293","citation_count":120,"is_preprint":false},{"pmid":"33972684","id":"PMC_33972684","title":"MALAT1 modulated FOXP3 ubiquitination then affected GINS1 transcription and drived NSCLC proliferation.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33972684","citation_count":42,"is_preprint":false},{"pmid":"30963468","id":"PMC_30963468","title":"Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma.","date":"2019","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/30963468","citation_count":41,"is_preprint":false},{"pmid":"34414190","id":"PMC_34414190","title":"GINS1 Induced Sorafenib Resistance by Promoting Cancer Stem Properties in Human Hepatocellular Cancer Cells.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34414190","citation_count":29,"is_preprint":false},{"pmid":"36065190","id":"PMC_36065190","title":"GINS1 promotes the proliferation and migration of glioma cells through USP15-mediated deubiquitination of TOP2A.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36065190","citation_count":28,"is_preprint":false},{"pmid":"38468464","id":"PMC_38468464","title":"GINS1 promotes ZEB1-mediated epithelial-mesenchymal transition and tumor metastasis via β-catenin signaling in hepatocellular carcinoma.","date":"2024","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/38468464","citation_count":16,"is_preprint":false},{"pmid":"36469009","id":"PMC_36469009","title":"A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.","date":"2023","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/36469009","citation_count":12,"is_preprint":false},{"pmid":"37221950","id":"PMC_37221950","title":"PAX5 and circ1857 affected DLBCL progression and B-cell proliferation through regulating GINS1.","date":"2023","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/37221950","citation_count":9,"is_preprint":false},{"pmid":"37576391","id":"PMC_37576391","title":"FOXP1-GINS1 axis promotes DLBCL proliferation and directs doxorubicin resistance.","date":"2023","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37576391","citation_count":9,"is_preprint":false},{"pmid":"39210373","id":"PMC_39210373","title":"OTU deubiquitinase, ubiquitin aldehyde binding 2  (OTUB2) modulates the stemness feature, chemoresistance, and epithelial-mesenchymal transition of colon cancer via regulating GINS complex subunit 1 (GINS1) expression.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/39210373","citation_count":8,"is_preprint":false},{"pmid":"37904396","id":"PMC_37904396","title":"Roles of DSCC1 and GINS1 in gastric cancer.","date":"2023","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37904396","citation_count":8,"is_preprint":false},{"pmid":"37824372","id":"PMC_37824372","title":"Transcription Factor E2F1 Enhances Hepatocellular Carcinoma Cell Proliferation and Stemness by Activating GINS1.","date":"2024","source":"Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37824372","citation_count":6,"is_preprint":false},{"pmid":"38880324","id":"PMC_38880324","title":"GINS1 promotes the initiation and progression of bladder cancer by activating the AKT/mTOR/c-Myc signaling pathway.","date":"2024","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38880324","citation_count":5,"is_preprint":false},{"pmid":"40713555","id":"PMC_40713555","title":"Epicatechin attenuates the stemness of liver cancer stem cells and tumorigenesis through DNA methylation-mediated inactivation of GINS1/HRAS.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40713555","citation_count":4,"is_preprint":false},{"pmid":"38301047","id":"PMC_38301047","title":"Complementary biomarkers of computed tomography for diagnostic grading of gastric cancer: DSCC1 and GINS1.","date":"2024","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/38301047","citation_count":4,"is_preprint":false},{"pmid":"40197379","id":"PMC_40197379","title":"GINS1 facilitates the development of lung adenocarcinoma via Wnt/β-catenin activation.","date":"2025","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40197379","citation_count":3,"is_preprint":false},{"pmid":"39631830","id":"PMC_39631830","title":"[GINS1 Enhances Glycolysis, Proliferation and Metastasis in Lung Adenocarcinoma Cells by Activating the Notch/PI3K/AKT/mTORC1 Signaling Pathway].","date":"2024","source":"Zhongguo fei ai za zhi = Chinese journal of lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39631830","citation_count":3,"is_preprint":false},{"pmid":"36451247","id":"PMC_36451247","title":"Identification of GINS1 as a therapeutic target in the cancer patients infected with COVID-19: a bioinformatics and system biology approach.","date":"2022","source":"Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/36451247","citation_count":2,"is_preprint":false},{"pmid":"41242545","id":"PMC_41242545","title":"Oncogenic GINS1 facilitates cervical cancer progression via FYN-mediated EMT regulation.","date":"2025","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41242545","citation_count":1,"is_preprint":false},{"pmid":"41776634","id":"PMC_41776634","title":"Unraveling the oncogenic and immunomodulatory roles of GINS1: a systematic pan-cancer study.","date":"2026","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/41776634","citation_count":0,"is_preprint":false},{"pmid":"41689265","id":"PMC_41689265","title":"Expanding Phenotype of GINS1 Deficiency: A Case Report and Review of the Literature.","date":"2026","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41689265","citation_count":0,"is_preprint":false},{"pmid":"41893924","id":"PMC_41893924","title":"Role of POLE2/GINS1-mediated AKT/mTOR pathway in RCC autophagy, proliferation, and metastasis: evidences from bioinformatic, clinical, and experimental data.","date":"2026","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/41893924","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14281,"output_tokens":4047,"usd":0.051774,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11890,"output_tokens":2760,"usd":0.064225,"stage2_stop_reason":"end_turn"},"total_usd":0.115999,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2017,\n      \"finding\": \"Biallelic loss-of-function mutations in GINS1 impair GINS complex assembly, cause basal replication stress, impaired checkpoint signaling, defective cell cycle control, and genomic instability in patient fibroblasts; residual GINS1 activity (3–16%) correlated with severity of growth retardation and cellular phenotype. Wild-type GINS1 rescued these defects, establishing GINS1 as essential for eukaryotic DNA replication complex function.\",\n      \"method\": \"Patient fibroblast studies (genetic rescue with WT GINS1, cell cycle analysis, checkpoint signaling assays, genomic instability assays); compound heterozygous mutation analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal cellular assays (replication stress, checkpoint, cell cycle, genomic instability) with genetic rescue, replicated across 5 patients from 4 kindreds\",\n      \"pmids\": [\"28414293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GINS1 physically interacts with TOP2A (Topoisomerase IIα) and promotes glioma cell proliferation and migration through USP15-mediated deubiquitination of TOP2A protein, thereby stabilizing TOP2A.\",\n      \"method\": \"Co-immunoprecipitation (physical interaction), functional assays (proliferation, migration in vitro and in vivo), mechanistic deubiquitination assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional rescue, single lab, two orthogonal methods\",\n      \"pmids\": [\"36065190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MALAT1 lncRNA stabilizes FOXP3 protein by binding to its zinc finger (ZF) and leucine zipper (LZ) domains, masking the STUB1 E3 ligase interaction interface and inhibiting K48-linked ubiquitination/degradation of FOXP3; stabilized FOXP3 then acts as a transcription factor driving GINS1 expression, thereby promoting NSCLC proliferation.\",\n      \"method\": \"Co-IP, domain mapping, luciferase reporter assay, in vitro/in vivo knockdown and rescue experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with domain mapping plus luciferase reporter, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33972684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NFIX transcription factor directly binds the GINS1 gene promoter (region −1779 to −1793 bp) and transcriptionally activates GINS1 expression; GINS1 is required for NFIX-driven GBM cell cycle progression and proliferation, and GINS1 replenishment rescues the anti-proliferative effect of NFIX knockdown.\",\n      \"method\": \"ChIP assay (promoter binding), luciferase reporter assay, genetic rescue experiments (GINS1 re-expression in NFIX-null cells)\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus luciferase reporter plus rescue, single lab, two orthogonal methods\",\n      \"pmids\": [\"36469009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PAX5 transcription factor directly binds two sites in the GINS1 promoter and functions as a positive transcriptional activator of GINS1, as demonstrated by EMSA, ChIP, and luciferase assays; coordinated PAX5/GINS1 expression was validated in B cells and DLBCL cell lines.\",\n      \"method\": \"EMSA, ChIP assay, luciferase reporter assay\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three orthogonal methods (EMSA, ChIP, luciferase), single lab\",\n      \"pmids\": [\"37221950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXP1 transcription factor directly binds the GINS1 promoter and transcriptionally activates GINS1 expression; the FOXP1-GINS1 regulatory axis promotes DLBCL cell proliferation and confers doxorubicin resistance.\",\n      \"method\": \"EMSA, ChIP assay, luciferase reporter assay, in vivo xenograft model, CCK8/colony formation assays\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three orthogonal methods (EMSA, ChIP, luciferase) with in vivo validation, single lab\",\n      \"pmids\": [\"37576391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"E2F1 transcription factor directly binds the GINS1 promoter and activates GINS1 transcription; E2F1-driven GINS1 expression promotes HCC cell proliferation and stemness (as measured by colony formation, CCK-8, sphere formation); rescue experiments confirmed that overexpressed E2F1 offsets the suppressive effect of GINS1 silencing.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, genetic rescue (E2F1 OE in GINS1 KD cells), sphere/colony/CCK-8 assays\",\n      \"journal\": \"Journal of environmental pathology, toxicology and oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus luciferase plus rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37824372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"OTUB2 deubiquitinase stabilizes SP1 protein by inhibiting its K48-linked ubiquitination; SP1 then binds the GINS1 promoter (region 1822–1830 bp) and transcriptionally activates GINS1, thereby driving stemness, chemoresistance, and EMT in colon cancer.\",\n      \"method\": \"Co-IP, ubiquitination assay, ChIP-qPCR, dual luciferase reporter assay, sphere formation, flow cytometry, cell viability assays\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, ubiquitination, ChIP-qPCR, luciferase), single lab\",\n      \"pmids\": [\"39210373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GINS1 knockdown causes G1/S cell cycle arrest and decreases tumor cell proliferation in HCC in vitro and in vivo; GINS1 promotes cancer stem cell activity (spheroid formation) and enhances HCC progression through activation of the HRAS signaling pathway; restoring HRAS partially rescued sorafenib resistance lost upon GINS1 knockdown.\",\n      \"method\": \"shRNA knockdown, cell cycle/proliferation assays, spheroid formation, xenograft mouse model, Western blot, RT-PCR, pathway rescue with HRAS overexpression\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined cellular phenotype plus pathway rescue, single lab, multiple methods\",\n      \"pmids\": [\"34414190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GINS1 directly interacts with HRAS (confirmed by co-immunoprecipitation and GST pulldown) and activates HRAS signaling, thereby inducing liver cancer stem cell phenotype and promoting tumorigenesis; epicatechin (EC) attenuates this axis by enhancing DNA methylation on the GINS1 promoter, reducing GINS1 expression.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown assay, methylation-specific PCR, sphere formation, CCK-8, transwell, xenograft tumor model\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct protein interaction confirmed by two methods (Co-IP and GST pulldown) plus functional rescue, single lab\",\n      \"pmids\": [\"40713555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GINS1 silencing inhibits the AKT/mTOR/c-Myc signaling pathway and causes G0/G1 cell cycle arrest in bladder cancer; conversely, increased GINS1 expression activates the AKT/mTOR pathway and accelerates bladder cancer progression in vitro and in vivo.\",\n      \"method\": \"siRNA knockdown, cell cycle/proliferation assays, colony formation, transwell migration, flow cytometry, Western blot, xenograft model\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway assessment by Western blot only, no rescue or mutagenesis\",\n      \"pmids\": [\"38880324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GINS1 promotes epithelial-mesenchymal transition (EMT) and HCC tumor metastasis through ZEB1 and the β-catenin signaling pathway; silencing GINS1 inhibits proliferation, migration, invasion and metastasis both in vitro and in vivo.\",\n      \"method\": \"shRNA knockdown, OE, EMT markers by Western blot, in vitro invasion/migration assays, in vivo xenograft/metastasis model\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway placement by Western blot without direct mechanistic validation of GINS1-β-catenin interaction\",\n      \"pmids\": [\"38468464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GINS1 promotes LUAD progression by activating the Wnt/β-catenin signaling pathway; transcriptome sequencing linked GINS1 to G1/S cell cycle transition (cyclin D) and β-catenin signaling, which was validated by Western blot and rescue experiments.\",\n      \"method\": \"Transcriptome sequencing, Western blot, rescue experiments (β-catenin pathway modulation), in vitro proliferation/migration assays, in vivo xenograft\",\n      \"journal\": \"World journal of surgical oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway assessed by Western blot and rescue, no direct binding assay for GINS1-β-catenin\",\n      \"pmids\": [\"40197379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GINS1 enhances glycolysis, proliferation, and metastasis in LUAD cells by upregulating Notch1 and Notch3 receptor expression, which activates downstream PI3K/AKT/mTORC1 signaling; Notch agonist Jagged1 reversed inhibition caused by GINS1 knockdown, and Notch inhibitor LY3039478 blocked enhancement caused by GINS1 overexpression.\",\n      \"method\": \"shRNA knockdown, OE, Western blot, glycolysis assays (glucose consumption, lactate production), colony formation, scratch, transwell, Notch agonist/inhibitor rescue experiments\",\n      \"journal\": \"Zhongguo fei ai za zhi = Chinese journal of lung cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway evidence by Western blot plus pharmacological rescue, no direct mechanistic link established between GINS1 and Notch receptors\",\n      \"pmids\": [\"39631830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GINS1 promotes EMT and tumor aggressiveness in cervical cancer by suppressing FYN kinase; GINS1 knockdown de-represses FYN and reduces EMT markers, establishing a GINS1/FYN/EMT regulatory axis.\",\n      \"method\": \"Transcriptome sequencing, in vitro functional assays (proliferation, migration, invasion, colony formation), xenograft model, Western blot and molecular analyses\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway placement by transcriptomics and Western blot, no direct binding or enzymatic assay linking GINS1 to FYN\",\n      \"pmids\": [\"41242545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"GINS1 is a downstream target of POLE2 in renal cell carcinoma; GINS1 overexpression reverses the inhibitory effects of POLE2 knockdown on RCC proliferation, metastasis, and EMT, and restores autophagy suppression. POLE2/GINS1 inhibits AKT/mTOR-mediated autophagy, thereby promoting EMT and lung metastasis.\",\n      \"method\": \"Bioinformatics, in vitro/in vivo models, GINS1 OE rescue of POLE2 KD, Western blot, molecular biology assays\",\n      \"journal\": \"Apoptosis : an international journal on programmed cell death\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway evidence primarily by rescue and Western blot, no direct binding assay for POLE2-GINS1 interaction\",\n      \"pmids\": [\"41893924\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GINS1 (PSF1/KIAA0186) is an essential subunit of the eukaryotic GINS complex required for DNA replication initiation and elongation; inherited partial loss-of-function mutations impair GINS complex assembly, cause replication stress, checkpoint defects, genomic instability, growth retardation, neutropenia, and NK cell deficiency. Beyond its core replication role, GINS1 expression is transcriptionally activated by multiple transcription factors (NFIX, PAX5, FOXP1, E2F1, SP1 downstream of OTUB2), and at the protein level GINS1 physically interacts with HRAS and TOP2A; the latter interaction is stabilized via USP15-mediated deubiquitination of TOP2A to drive glioma proliferation and migration, while GINS1-HRAS interaction promotes liver cancer stem cell properties, and GINS1 additionally modulates downstream oncogenic signaling (AKT/mTOR, Wnt/β-catenin, Notch/PI3K, FYN/EMT axes) across multiple cancer contexts.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GINS1 (PSF1) is an essential subunit of the eukaryotic GINS complex required for DNA replication, and biallelic loss-of-function mutations impair GINS complex assembly, producing basal replication stress, defective checkpoint signaling, impaired cell cycle control, and genomic instability, with residual GINS1 activity correlating with clinical severity in affected patients [#0]. Beyond this core replication role, GINS1 expression is a convergence point for multiple oncogenic transcription factors that directly bind its promoter and activate transcription, including NFIX [#3], PAX5 [#4], FOXP1 [#5], E2F1 [#6], and SP1 acting downstream of OTUB2 [#7]; FOXP3 stabilized by MALAT1 likewise drives GINS1 expression [#2]. At the protein level GINS1 physically interacts with TOP2A, and through USP15-mediated deubiquitination and stabilization of TOP2A it promotes glioma proliferation and migration [#1], and it directly binds HRAS to activate HRAS signaling and induce liver cancer stem cell phenotypes [#8, #9]. Across these contexts GINS1 supports the G1/S cell cycle transition and tumor cell proliferation [#6, #8].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2017,\n      \"claim\": \"Whether GINS1 is genuinely essential for human DNA replication and how its dosage maps to disease was unknown; patient-derived mutations established GINS1 as required for GINS complex assembly and replication integrity.\",\n      \"evidence\": \"Patient fibroblast studies with WT GINS1 genetic rescue, checkpoint, cell cycle and genomic instability assays across 5 patients from 4 kindreds\",\n      \"pmids\": [\"28414293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve the structural basis of how specific mutations impair GINS subunit assembly\", \"Does not address GINS1 function outside the replication context\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"It was unclear how GINS1 contributes to tumor aggressiveness beyond replication; loss-of-function studies linked GINS1 to HRAS pathway activation and cancer stem cell properties in HCC.\",\n      \"evidence\": \"shRNA knockdown with G1/S arrest, spheroid formation, xenografts and HRAS overexpression rescue\",\n      \"pmids\": [\"34414190\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not yet demonstrate a direct GINS1-HRAS physical interaction\", \"Mechanism of HRAS pathway engagement by a replication factor unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"How GINS1 transcription is upregulated in cancer was unaddressed; MALAT1-stabilized FOXP3 was shown to drive GINS1 expression in NSCLC.\",\n      \"evidence\": \"Co-IP, domain mapping, luciferase reporter, knockdown/rescue in vitro and in vivo\",\n      \"pmids\": [\"33972684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct FOXP3 binding to the GINS1 promoter not mapped at nucleotide resolution\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Whether GINS1 has protein partners that act outside replication was open; GINS1 was shown to physically interact with TOP2A and stabilize it via USP15-mediated deubiquitination to drive glioma growth.\",\n      \"evidence\": \"Reciprocal Co-IP, deubiquitination assays, proliferation/migration assays in vitro and in vivo\",\n      \"pmids\": [\"36065190\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How GINS1 promotes USP15 recruitment to TOP2A not defined\", \"Single lab without independent replication\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The transcriptional control of GINS1 was clarified by identifying multiple direct promoter-binding activators across cancer types: NFIX, PAX5 and FOXP1.\",\n      \"evidence\": \"ChIP/EMSA promoter binding, luciferase reporter and rescue assays in GBM, B cells/DLBCL\",\n      \"pmids\": [\"36469009\", \"37221950\", \"37576391\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether these factors act combinatorially on the same promoter is unknown\", \"Each shown in a distinct single-lab context\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Additional transcriptional inputs were established, placing GINS1 downstream of E2F1 and of OTUB2-stabilized SP1.\",\n      \"evidence\": \"ChIP, dual-luciferase reporter, ubiquitination assays and rescue in HCC and colon cancer\",\n      \"pmids\": [\"37824372\", \"39210373\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Hierarchy among the many GINS1 activators not resolved\", \"Single lab per context\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The earlier functional link to HRAS was upgraded to a direct physical interaction, defining a GINS1-HRAS axis driving liver cancer stem cell phenotypes.\",\n      \"evidence\": \"Co-IP and GST pulldown, methylation-specific PCR, sphere formation and xenografts\",\n      \"pmids\": [\"40713555\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction interface and stoichiometry not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"GINS1 was placed upstream of several oncogenic signaling cascades across tumor types, though largely by pathway-level readouts.\",\n      \"evidence\": \"Knockdown/overexpression with Western blot and pharmacological rescue assigning GINS1 to AKT/mTOR, β-catenin, Notch/PI3K and FYN/EMT axes\",\n      \"pmids\": [\"38880324\", \"38468464\", \"39631830\", \"41242545\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct binding or enzymatic assay linking GINS1 to these pathway nodes\", \"Pathway placement rests on Western blot and rescue, prone to indirect effects\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"GINS1 was positioned as a downstream effector of POLE2 controlling AKT/mTOR-mediated autophagy in renal cell carcinoma.\",\n      \"evidence\": \"Bioinformatics with GINS1 overexpression rescue of POLE2 knockdown, in vitro/in vivo models, Western blot\",\n      \"pmids\": [\"41893924\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct POLE2-GINS1 binding assay\", \"Single lab, indirect pathway evidence\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How GINS1's essential replication function mechanistically intersects with its many reported oncogenic interactions and transcriptional inputs remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of GINS1 within the human GINS complex from the corpus\", \"Whether non-replication interactions (HRAS, TOP2A) depend on or are separable from GINS complex assembly is unknown\", \"Causal hierarchy among the numerous transcription factors driving GINS1 not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [\"GINS complex\"],\n    \"partners\": [\"TOP2A\", \"HRAS\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":4,"faith_total":4,"faith_pct":100.0}}